SVB Securities analyst Joseph Schwartz initiated coverage of PTC Therapeutics with a Market Perform rating and $48 price target.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PTCT:
- PTC Therapeutics management to meet with Cantor Fitzgerald
- PTC Therapeutics price target raised to $51 from $44 at RBC Capital
- PTC Therapeutics price target lowered to $66 from $68 at Cantor Fitzgerald
- PTC Therapeutics reports Q4 EPS ($2.35), consensus ($1.59)
- PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results